Skip to main content
. Author manuscript; available in PMC: 2013 Nov 25.
Published in final edited form as: Cell Prolif. 2011 Jun 6;44(4):10.1111/j.1365-2184.2011.00757.x. doi: 10.1111/j.1365-2184.2011.00757.x

Figure 5. CXCL13 regulates PCa cell proliferation through JNK and DOCK2.

Figure 5

RWPE-1, LNCaP, and PC3 cells were grown in reduced serum conditions (2% FBS) in presence or absence of CXCL13 (100 ng/ml), isotype control antibody or anti-CXCR5 antibody (1 μg/ml), DOCK2siRNA or control siRNA (2 μM), and/or JNK inhibitor (10 μM). MTT assay was performed every 24 h for 3 days to assess cell proliferation. Error bars represent ± standard error of means of three independent experiments. *Significant (P < 0.05) changes relative to CXCL13-treated cells.